Global Information
회사소개 | 문의

세계의 액체생검 시장 분석과 예측(2018-2028년)

Global Liquid Biopsy Market: Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, Country Analysis (16 Countries), Industry Insights, and Competitive Landscape - Analysis and Forecast, 2018-2028

리서치사 BIS Research Inc.
발행일 2018년 10월 상품 코드 587014
페이지 정보 영문 315 Pages
가격
US $ 5,000 ₩ 5,740,000 Unprintable PDF by E-mail (Single User License)
US $ 5,500 ₩ 6,314,000 Hard Copy
US $ 6,500 ₩ 7,462,000 Printable PDF by E-mail (Single Site License)
US $ 8,000 ₩ 9,184,000 Printable PDF and Excel by E-mail (Enterprise-wide License)


세계의 액체생검 시장 분석과 예측(2018-2028년) Global Liquid Biopsy Market: Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, Country Analysis (16 Countries), Industry Insights, and Competitive Landscape - Analysis and Forecast, 2018-2028
발행일 : 2018년 10월 페이지 정보 : 영문 315 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계 액체생검 시장 규모는 2018-2028년간 14.45%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2028년까지 29억 4,000만 달러에 이를 것으로 예측됩니다.

세계의 액체생검(Liquid Biopsy) 시장을 분석했으며, 시장 개요, 주요 시장 영향요인, 시장 경쟁 환경, 시장 규모 동향 전망, 순환 바이오마커·제품·치료 용도·임상 용도·지역별 동향, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

주요 요약

제1장 시장 개요

제2장 시장 역학

  • 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제3장 경쟁 분석

  • 주요 전략과 발전
  • 시장 점유율 분석
  • 성장 점유율 분석
  • 세계의 CCI(Comprehensive Competitive Index)
  • 산업의 매력

제4장 산업 분석

  • 서론
  • 특허 분석
  • 자금 현황
  • 규제 단체
  • CLIA 프로그램
  • 정부 이니셔티브

제5장 세계의 액체생검 시장 : 순환 바이오마커

  • 순환 종양 DNA(ctDNA)
  • 순환 종양 세포(CTC)
  • Cell-Free DNA (cfDNA)
  • 세포외 소포(EV), 기타

제6장 세계의 액체생검 시장 : 제품별

  • 테스트/서비스
  • 키트 및 소모품
  • 장비

제7장 세계의 액체생검 시장 : 치료 용도별

  • 폐암
  • 유방암
  • 전립선암
  • 대장암
  • 흑색종
  • 기타 암
  • 암 이외 용도

제8장 세계의 액체생검 시장 : 임상 용도

  • 치료 모니터링
  • 예후 및 재발 모니터링
  • 치료 선택
  • 진단 및 스크리닝

제9장 세계의 액체생검 시장 : 지역별

  • 국가별 성장 가능성 분석 : 세계의 액체생검 시장
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카 및 중동
  • 기타

제10장 기업 개요

  • Abcodia Ltd.
    • 기업 개요
    • 시장의 역할
    • SWOT 분석 등
  • Adaptive Biotechnologies
  • ANGLE plc
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cynvenio Biosystems, Inc.
  • Chronix Biomedical
  • Epic Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • GUARDANT HEALTH, INC
  • Illumina, Inc.
  • MDxHealth, Inc.
  • Menarini Silicon Biosystems, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personal Genome Diagnostics, Inc.
  • QIAGEN
  • Resolution Bioscience, Inc.
  • Sysmex
  • Thermo Fisher Scientific

제11장 조사 범위와 조사 방법

LSH 18.10.11

List of Tables

  • Table 1: Cancer Incidences (by Region), 2015
  • Table 1.1: Tissue Biopsy vs. Liquid Biopsy
  • Table 2.1: Impact Analysis
  • Table 2.2: Governmental Initiatives for the Market Growth of Precision Medicine
  • Table 2.3: Incidence of Leading Cancer Types (by Region), 2015
  • Table 4.1: List of Regulatory Bodies across the World
  • Table 4.2: List of Regulatory Authorities involved in CLIA Program
  • Table 4.3: Government Initiatives
  • Table 7.1: Lung Cancer Incidence in Top Countries, 2012-2030
  • Table 7.2: Breast Cancer Incidence in Top Countries, 2012-2030
  • Table 7.3: Prostate Cancer Incidence in Top Countries, 2012-2030
  • Table 7.4: Colorectal Cancer Incidence in Top Countries, 2012-2030
  • Table 7.5: Estimated Incidence and Mortality of Melanoma Worldwide in 2012
  • Table 7.6: Melanoma Cancer Incidence in Top Countries, 2012-2030
  • Table 7.7: Ovarian Cancer Incidence in Top Countries, 2012-2030
  • Table 7.8: Stomach Cancer Incidence in Top Countries, 2012-2030
  • Table 9.1: Analysis of Growth Potential (by Countries)
  • Table 9.2: Prevalence of Different Types of Cancer (by Country), 2017
  • Table 9.3: Prevalence of Different Types of Cancer (by Country), 2017
  • Table 9.4: The U.S: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.5: Canada: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.6: Germany: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.7: France: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.8: The U.K.: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.9: Italy: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.10: Spain: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.11: China: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.12: Japan: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.13: India: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.14: Australia: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.15: South Korea: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.16: Singapore: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.17: Brazil: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.18: Mexico: Prevalence of Different Types of Cancer, 2015-2030
  • Table 9.19: Saudi Arabia: Prevalence of Different Types of Cancer, 2015-2030

List of Figures

  • Figure 1: Few Citations of Liquid Biopsy
  • Figure 2: Facts about Cancer
  • Figure 3: Market Drivers and Market Restraints
  • Figure 4: Market Statistics
  • Figure 5: Global Liquid Biopsy Market, 2017-2028
  • Figure 6: Global Liquid Biopsy Market (by Products), 2017 and 2028
  • Figure 7: Global Liquid Biopsy Market (by Circulating Biomarker), 2017-2028
  • Figure 8: Global Liquid Biopsy Market (by Clinical Application), 2017-2028
  • Figure 9: Global Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 10: Global Liquid Biopsy Market (by Region), 2017-2028
  • Figure 11: Adoption Rate: Tissue Biopsy vs. Liquid biopsy
  • Figure 1.1: Different Types of Biomarkers in Liquid Biopsy
  • Figure 1.2: Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
  • Figure 1.3: Workflow Model of Tissue and Liquid Biopsy
  • Figure 1.4: Clinical Applications of Liquid Biopsy
  • Figure 1.5: Global Liquid Biopsy Market, 2017-2028
  • Figure 2.1: Market Dynamics of Global Liquid Biopsy Market
  • Figure 3.1: Competitive Landscape, January 2015-July 2018
  • Figure 3.2: Share of Key Developments and Strategies, January 2015-July 2018
  • Figure 3.3: Mergers and Acquisitions Share (by Companies), January 2015-July 2018
  • Figure 3.4: Business Expansions Share (by Companies), January 2015-July 2018
  • Figure 3.5: Awards, Recognitions, Certifications and Others Share (by Companies), January 2015-July 2018
  • Figure 3.6: Product Launches Share (by Companies), January 2015-July 2018
  • Figure 3.7: Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-July 2018
  • Figure 3.8: Market Share Analysis: Global Liquid Biopsy Market, 2016 and 2017
  • Figure 3.9: Growth Share Matrix for Global Liquid Biopsy Market (by Prominent Companies), 2018-2020
  • Figure 3.10: Growth Share Matrix for Global Liquid Biopsy Market (by Therapeutic Application), 2017
  • Figure 3.11: Growth Share Matrix for Global Liquid Biopsy Market (by Biomarker Type), 2017
  • Figure 3.12: Growth Share Matrix for Global Liquid Biopsy Market (by Clinical Application), 2017
  • Figure 3.13: Global Comprehensive Competitive Index (by Market Leaders), 2017
  • Figure 3.14: Porter's Five Forces Analysis
  • Figure 3.15: Bargaining Power of Suppliers: Overall Impact, 2014-2028
  • Figure 3.16: Bargaining Power of Buyers: Overall Impact, 2014-2028
  • Figure 3.17: Threat of New Entrant: Overall Impact, 2014-2028
  • Figure 3.18: Threat of Substitute Products: Overall Impact, 2014-2028
  • Figure 3.19: Intensity of Competitive Rivalry: Overall Impact, 2014-2028
  • Figure 4.1: Industry Insights, January 2015-May 2018
  • Figure 4.2: Patent Share (by Assignee), January 2015-July 2018
  • Figure 4.3: Research Investments by Companies, $Million, January 2015-Decemeber 2017
  • Figure 4.4: Categorization of Test Methods (by FDA)
  • Figure 5.1: Different Circulating Biomarkers
  • Figure 5.2: Global Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2028
  • Figure 5.3: Global Liquid Biopsy Market (by cTDNA), 2017-2028
  • Figure 5.4: CTCs vs. cTDNA Analysis
  • Figure 5.5: Global Liquid Biopsy Market (by CTCs), 2017-2028
  • Figure 5.6: Global Liquid Biopsy Market (by cfDNA), 2017-2028
  • Figure 5.7: Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2028
  • Figure 6.1: Global Liquid Biopsy Market (by Products)
  • Figure 6.2: Global Liquid Biopsy Market (by Products), 2017-2028
  • Figure 6.3: Global Liquid Biopsy Market (by Tests/Services), 2017-2028
  • Figure 6.4: Global Liquid Biopsy Market (by Kits and Consumables), 2017-2028
  • Figure 6.5: Global Liquid Biopsy Market (by Instruments), 2017-2028
  • Figure 7.1: Global Liquid Biopsy Market (by Therapeutic Application)
  • Figure 7.2: Global Liquid Biopsy Market (by Therapeutic Applications), 2017-2028
  • Figure 7.3: Types of Lung Cancer
  • Figure 7.4: Global Liquid Biopsy Market (by Lung Cancer), 2017-2028
  • Figure 7.5: Types of Breast Cancer
  • Figure 7.6: Global Liquid Biopsy Market (by Breast Cancer), 2017-2028
  • Figure 7.7: Global Liquid Biopsy Market (by Prostate Cancer), 2017-2028
  • Figure 7.8: Global Liquid Biopsy Market (by Colorectal Cancer), 2017-2028
  • Figure 7.9: Global Liquid Biopsy Market (by Melanoma Cancer), 2017-2028
  • Figure 7.10: Global Liquid Biopsy Market (by Other Types of Cancer), 2017-2028
  • Figure 7.11: Global Liquid Biopsy Market (by Non-Oncology Applications), 2017-2028
  • Figure 8.1: Global Liquid Biopsy Market (by Clinical Applications)
  • Figure 8.2: Global Liquid Biopsy Market (by Clinical Applications), 2017-2028
  • Figure 8.3: Global Liquid Biopsy Market (by Treatment Monitoring), 2017-2028
  • Figure 8.4: Global Liquid Biopsy Market (by Prognosis and Reoccurrence Monitoring), 2017-2028
  • Figure 8.5: Global Liquid Biopsy Market (by Treatment Selection), 2017-2028
  • Figure 8.6: Global Liquid Biopsy Market (by Diagnosis and Screening), 2017-2028
  • Figure 9.1: Global Liquid Biopsy Market Scenario, 2017 and 2028
  • Figure 9.2: Global Liquid Biopsy Market (by Region), 2017-2028
  • Figure 9.3: Global Liquid Biopsy Market Share (by Region), 2017 and 2028
  • Figure 9.4: Cluster Analysis: Global Liquid Biopsy Market
  • Figure 9.5: Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
  • Figure 9.6: Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
  • Figure 9.7: Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
  • Figure 9.8: Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
  • Figure 9.9: North America: Liquid Biopsy Market, (2017-2028)
  • Figure 9.10: North America: Market Dynamics
  • Figure 9.11: North America: Liquid biopsy Market (by Country), 2017-2028
  • Figure 9.12: The U.S: Liquid Biopsy Market, 2017-2028
  • Figure 9.13: The U.S: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.14: Canada: Liquid Biopsy Market, 2017-2028
  • Figure 9.15: Canada: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.16: Europe: Liquid Biopsy Market, 2017-2028
  • Figure 9.17: Europe: Market Dynamics
  • Figure 9.18: Europe: Liquid Biopsy Market (by Country), 2017-2028
  • Figure 9.19: Germany: Liquid Biopsy Market, 2017-2028
  • Figure 9.20: Germany: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.21: France: Liquid Biopsy Market, 2017-2028
  • Figure 9.22: France: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.23: The U.K.: Liquid Biopsy Market, 2017-2028
  • Figure 9.24: The U.K.: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.25: Italy: Liquid Biopsy Market, 2017-2028
  • Figure 9.26: Italy: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.27: Spain: Liquid Biopsy Market, 2017-2028
  • Figure 9.28: Spain: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.29: Rest-of-Europe: Liquid Biopsy Market, 2017-2028
  • Figure 9.30: Asia-Pacific: Liquid Biopsy Market, 2017-2028
  • Figure 9.31: Asia-Pacific: Market Dynamics
  • Figure 9.32: Asia Pacific: Liquid Biopsy Market (by Country), 2017-2028
  • Figure 9.33: China: Liquid Biopsy Market, 2017-2028
  • Figure 9.34: China: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.35: Japan: Liquid Biopsy Market, 2017-2028
  • Figure 9.36: Japan: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.37: India: Liquid Biopsy Market, 2017-2028
  • Figure 9.38: India: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.39: Australia: Liquid Biopsy Market, 2017-2028
  • Figure 9.40: Australia: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.41: South Korea: Liquid Biopsy Market, 2017-2028
  • Figure 9.42: South Korea: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.43: Singapore: Liquid Biopsy Market, 2017-2028
  • Figure 9.44: Singapore: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.45: Rest-of-Asia Pacific: Liquid Biopsy Market, 2017-2028
  • Figure 9.46: Latin America: Liquid Biopsy Market, 2017-2028
  • Figure 9.47: Latin America: Market Dynamics
  • Figure 9.48: Latin America: Liquid Biopsy Market (by Country), 2017-2028
  • Figure 9.49: Brazil: Liquid Biopsy Market, 2017-2028
  • Figure 9.50: Brazil: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.51: Mexico: Liquid Biopsy Market, 2017-2028
  • Figure 9.52: Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.53: Saudi Arabia: Liquid Biopsy Market, 2017-2028
  • Figure 9.54: Saudi Arabia: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
  • Figure 9.55: Rest-of-Latin America and Middle East: Liquid Biopsy Market, 2017-2028
  • Figure 9.56: Rest-of-the-World: Liquid Biopsy Market, 2017-2028
  • Figure 10.1: Shares of Key Company Profiles
  • Figure 10.2: Abcodia Ltd.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.3: Abcodia Ltd.: SWOT Analysis
  • Figure 10.4: Adaptive Biotechnologies: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.5: Adaptive Biotechnologies: SWOT Analysis
  • Figure 10.6: ANGLE plc: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.7: ANGLE plc: Overall Financials, 2015-2017
  • Figure 10.8: ANGLE plc: Revenue (by Region), 2016 and 2017
  • Figure 10.9: ANGLE plc: R&D Expense, 2015-2017
  • Figure 10.10: ANGLE plc: Revenue Forecast, 2015-2020
  • Figure 10.11: ANGLE plc: Global Presence
  • Figure 10.12: ANGLE plc: SWOT Analysis
  • Figure 10.13: Biocept, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.14: Biocept, Inc.: Overall Financials, 2015-2017
  • Figure 10.15: Biocept, Inc.: R&D Expense, 2015-2017
  • Figure 10.16: Biocept, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.17: Biocept, Inc.: SWOT Analysis
  • Figure 10.18: Bio-Rad Laboratories, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.19: Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
  • Figure 10.20: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 10.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.22: Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
  • Figure 10.23: Bio-Rad Laboratories, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.24: Bio-Rad Laboratories, Inc.: Global Presence
  • Figure 10.25: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 10.26: Cynvenio Biosystems, Inc.: Overall Product Portfolio
  • Figure 10.27: Cynvenio Biosystems, Inc.: SWOT Analysis
  • Figure 10.28: Chronix Biomedical: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.29: Chronix Biomedical: SWOT Analysis
  • Figure 10.30: Epic Sciences, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.31: Epic Sciences, Inc.: SWOT Analysis
  • Figure 10.32: F. Hoffmann-La Roche AG: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.33: F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
  • Figure 10.34: F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
  • Figure 10.35: F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
  • Figure 10.36: F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
  • Figure 10.37: F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
  • Figure 10.38: F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
  • Figure 10.39: F. Hoffmann-La Roche AG: Global Presence
  • Figure 10.40: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 10.41: GUARDANT HEALTH, INC.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.42: GUARDANT HEALTH, INC.: SWOT Analysis
  • Figure 10.43: Illumina, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.44: Illumina, Inc.: Overall Financials, 2015-2017
  • Figure 10.45: Illumina, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 10.46: Illumina, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.47: Illumina, Inc.: R&D Expense, 2015-2017
  • Figure 10.48: Illumina, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.49: Illumina, Inc.: Global Presence
  • Figure 10.50: Illumina, Inc.: SWOT Analysis
  • Figure 10.51: MDxHealth, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.52: MDxHealth, Inc.: Overall Financials, 2015-2017
  • Figure 10.53: MDxHealth, Inc.: R&D Expanse, 2015-2017
  • Figure 10.54: MDxHealth, Inc.: Revenue Forecast, 2015-2017
  • Figure 10.55: MDxHealth, Inc.: Global Presence
  • Figure 10.56: MDxHealth, Inc.: SWOT Analysis
  • Figure 10.57: Menarini Silicon Biosystems, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.58: Menarini Silicon Biosystems, Inc.: SWOT Analysis
  • Figure 10.59: Myriad Genetics, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.60: Myriad Genetics, Inc.: Overall Financials, 2015-2017
  • Figure 10.61: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 10.62: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.63: Myriad Genetics, Inc.: R&D Expense, 2015-2017
  • Figure 10.64: Myriad Genetics, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.65: Myriad Genetics, Inc.: Global Presence
  • Figure 10.66: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 10.67: Natera, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.68: Natera, Inc.: Overall Financials, 2015-2017
  • Figure 10.69: Natera, Inc.: Revenue (by Region), 2015-2017
  • Figure 10.70: Natera, Inc.: R&D Expense, 2015-2017
  • Figure 10.71: Natera, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.72: Natera, Inc.: Global Presence
  • Figure 10.73: Natera, Inc.: SWOT Analysis
  • Figure 10.74: NeoGenomics Laboratories, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.75: NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
  • Figure 10.76: NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 10.77: NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
  • Figure 10.78: NeoGenomics Laboratories, Inc.: Revenue Forecast, 2015-2020
  • Figure 10.79: NeoGenomics Laboratories, Inc.: Global Presence
  • Figure 10.80: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 10.81: Personal Genome Diagnostics, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.82: Personal Genome Diagnostics, Inc.: SWOT Analysis
  • Figure 10.83: Qiagen N.V.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.84: Qiagen N.V.: Overall Financials, 2015-2017
  • Figure 10.85: Qiagen N.V.: Revenue (by Business Segment), 2015-2017
  • Figure 10.86: Qiagen N.V.: Revenue (by Region), 2015-2017
  • Figure 10.87: Qiagen N.V.: R&D Expense, 2015-2017
  • Figure 10.88: Qiagen N.V.: Revenue Forecast, 2015-2020
  • Figure 10.89: Qiagen N.V.: Global Presence
  • Figure 10.90: Qiagen N.V.: SWOT Analysis
  • Figure 10.91: Resolution Bioscience, Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.92: Resolution Bioscience, Inc.: SWOT Analysis
  • Figure 10.93: Sysmex Corporation: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.94: Sysmex Corporation: Overall Financials, 2015-2017
  • Figure 10.95: Sysmex Corporation: Revenue (by Business Segment), 2016 and 2017
  • Figure 10.96: Sysmex Corporation: Revenue (by Business Segment), 2015
  • Figure 10.97: Sysmex Corporation: Revenue by Product Type (2015-2017)
  • Figure 10.98: Sysmex Corporation: Revenue (by Region), 2015-2017
  • Figure 10.99: Sysmex Corporation: R&D Expense, 2015-2017
  • Figure 10.100: Sysmex Corporation: Revenue Forecast, 2015-2020
  • Figure 10.101: Sysmex Corporation: Global Presence
  • Figure 10.102: Sysmex Corporation: SWOT Analysis
  • Figure 10.103: Thermo Fisher Scientific Inc.: Product Offerings for Global Liquid Biopsy Market
  • Figure 10.104: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
  • Figure 10.105: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 10.106: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
  • Figure 10.107: Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
  • Figure 10.108: Thermo Fisher Scientific Inc.: Revenue Forecast, 2015-2020
  • Figure 10.109: Thermo Fisher Scientific Inc.: Global Presence
  • Figure 10.110: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 11.1: Global Liquid Biopsy: Market Segmentation
  • Figure 11.2: Global Liquid Biopsy Market Segmentation
  • Figure 11.3: Primary Research
  • Figure 11.4: Secondary Research
  • Figure 11.5: Data Triangulation
  • Figure 11.6: Top-down Approach (Segment-wise Analysis)
  • Figure 11.7: Bottom-up Approach (Segment-wise Analysis)
  • Figure 11.8: Assumptions and Limitations
  • Figure 11.9: Considered Factors for Data Prediction and Modelling

영문목차

The global liquid biopsy market is anticipated to reach $2.94 billion by 2028, witnessing a CAGR of 14.45% in the forecast period 2018-2028.

Tissue biopsy is the predominant diagnostic procedure that is used for cancer diagnosis and treatment monitoring. Tissue biopsy is essentially dependent on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too. This has elevated the requirement for novel diagnostic approaches. The search for better minimal invasive diagnostic procedures aimed at aiding regular monitoring of a patient's response toward the treatment resulted in the evolution of liquid biopsy tests. Recent research on cancer biomarkers' presence in biological fluids, such as blood which can be collected through minimal invasive techniques, has yielded promising results to develop better minimal invasive diagnostics procedures known as liquid biopsy.

Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results aid the doctors in deciding the further steps in the treatment of the patients suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.

The purpose of this study is to gain a holistic view of the liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global liquid biopsy market. The market has been segmented into “Biomarker”, “Clinical Applications”, “Therapeutic Applications”, “Products and Services”, and “Region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global liquid biopsy market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global liquid biopsy market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of liquid biopsy market in each region for different cancer types, and the key strategies and developments by the prominent liquid biopsy market stake holders.

The answers to the following key questions can be derived from this report:

  • What are the key features of the liquid biopsy technology promoting its incorporation in different clinical applications?
  • What are the key advantages of the liquid biopsy technology over tissue biopsy?
  • How did the liquid biopsy market evolve and what is its scope in the future?
  • What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?
  • What are the key developmental strategies which are implemented by the key players to stand out in this market?
  • What are the leading companies dominating the global liquid biopsy market?
  • Which therapeutic application market would witness massive incorporation of the liquid biopsy technology in the forecast period?
  • Products based on which circulating biomarker are anticipated to witness massive rise in their demand in the forecast period?
  • How would the scope of clinical application of the liquid biopsy technology evolve in the forecast period?
  • What are investors' perceptions about the global liquid biopsy market?
  • Who are the leading stakeholders of the market holding significant share in the market's intellectual property?
  • What are the key companies which made substantial investments to aid technological advancements in the market?
  • What are the regulations pertaining to the global liquid biopsy market?
  • What are initiatives implemented by different government bodies to combat the growing prevalence of different types of cancer?
  • What was the market value of the leading segments and sub-segments of the global liquid biopsy market?
  • How will each segment of the global liquid biopsy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
  • How will the industry evolve during the forecast period 2018-2028?
  • Which geographical location will contribute to the highest sales of the global liquid biopsy market during the forecast period?

The key players who have been contributing significantly to the liquid biopsy market are: Biocept Inc., Bio-Rad Laboratories Inc., Guardant Health, Inc., Myriad Genetics, QIAGEN, RainDance Technologies, Roche AG, Trovagene Inc., Adaptive Biotechnologies, Natera, Inc., Cynvenio Biosystems, Inc., Epic Sciences, ANGLE plc, Illumina, Inc., Menarini Silicon Biosystems., MDxHealth, Sysmex Inostics GmbH, Genomic Health, and NeoGenomics Laboratories, Inc., among others.

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. Historical Trends
  • 1.2. Comparative Analysis of Tissue Biopsy and Liquid Biopsy
  • 1.3. Clinical Applications of Liquid Biopsy
  • 1.4. Trends for Liquid Biopsy
  • 1.5. Assumptions and Limitations for Market Size Calculations
  • 1.6. Global Liquid Biopsy Market Scenario

2. Market Dynamics

  • 2.1. Impact Analysis
  • 2.2. Market Drivers
    • 2.2.1. Potential of Liquid Biopsy
    • 2.2.2. Ability to Monitor Clonal Mutations
    • 2.2.3. Growing Prominence of Precision Medicine
  • 2.3. Market Restraints
    • 2.3.1. Uncertain Reimbursement and Regulatory Policies
    • 2.3.2. High Pricing Pressure
    • 2.3.3. Adoption of Traditional Diagnosis Practices
  • 2.4. Market Opportunities
    • 2.4.1. Development of Medication Package Deals
    • 2.4.2. Expansion into Emerging markets
    • 2.4.3. Scope of Liquid Biopsy for Intervention: Diagnosis of Non-oncology Disorders

3. Competitive Insights

  • 3.1. Key Strategies and Developments
    • 3.1.1. Mergers and Acquisitions
    • 3.1.2. Business Expansions
    • 3.1.3. Awards, Recognitions, Certifications, and Others
    • 3.1.4. Product Launches and Enhancements
    • 3.1.5. Joint Ventures, Partnerships, and Collaborations
  • 3.2. Market Share Analysis
  • 3.3. Growth Share Analysis
    • 3.3.1. Growth Share Analysis (by Prominent Companies)
    • 3.3.2. Growth Share Analysis (by Therapeutic Application)
    • 3.3.3. Growth Share Analysis (by Biomarker Type)
    • 3.3.4. Growth Share Analysis (by Clinical Application)
  • 3.4. Global Comprehensive Competitive Index (CCI)
  • 3.5. Industry Attractiveness
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyer
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitute Products
    • 3.5.5. Intensity of Competitive Rivalry

4. Industry Insights

  • 4.1. Introduction
  • 4.2. Patent Analysis
  • 4.3. Funding Scenario
  • 4.4. Regulatory Bodies
  • 4.5. Clinical Laboratory Improvement Amendments (CLIA) Program
  • 4.6. Government Initiatives

5. Global Liquid Biopsy Market (by Circulating Biomarkers)

  • 5.1. Circulating Tumor DNA (cTDNA)
  • 5.2. Circulating Tumor Cells (CTCs)
  • 5.3. Cell-Free DNA (cfDNA)
  • 5.4. Extracellular Vesicles and Others

6. Global Liquid Biopsy Market (by Products)

  • 6.1. Tests/Services
  • 6.2. Kits and Consumables
  • 6.3. Instruments

7. Global Liquid Biopsy Market (by Therapeutic Application)

  • 7.1. Lung Cancer
  • 7.2. Breast Cancer
  • 7.3. Prostate Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Melanoma Cancer
  • 7.6. Other Types of Cancer
  • 7.7. Non-Oncology Application

8. Global Liquid Biopsy Market (by Clinical Applications)

  • 8.1. Treatment Monitoring
  • 8.2. Prognosis and Reoccurrence Monitoring
  • 8.3. Treatment Selection
  • 8.4. Diagnosis and Screening

9. Global Liquid Biopsy Market (by Region)

  • 9.1. Analysis of Growth Potential of Different Countries: Global Liquid Biopsy Market
    • 9.1.1. Cluster-1: China and India
    • 9.1.2. Cluster-2: The U.S. and Japan
    • 9.1.3. Cluster-3: Brazil, South Korea, Spain, Italy, The U.K., France, and Canada
    • 9.1.4. Cluster-4: Germany, Australia, Singapore, Mexico, and Saudi Arabia
  • 9.2. North America
    • 9.2.1. The U.S.
      • 9.2.1.1. U.S. Liquid Biopsy Market (by Therapeutic Application)
    • 9.2.2. Canada
      • 9.2.2.1. Canada Liquid Biopsy Market (by Therapeutic Application)
  • 9.3. Europe
    • 9.3.1. Germany
      • 9.3.1.1. Germany Liquid Biopsy Market (by Therapeutic Application)
    • 9.3.2. France
      • 9.3.2.1. France Liquid Biopsy Market (by Therapeutic Application)
    • 9.3.3. The U.K.
      • 9.3.3.1. U.K. Liquid Biopsy Market (by Therapeutic Application)
    • 9.3.4. Italy
      • 9.3.4.1. Italy Liquid Biopsy Market (by Therapeutic Application)
    • 9.3.5. Spain
      • 9.3.5.1. Spain Liquid Biopsy Market (by Therapeutic Application)
    • 9.3.6. Rest-of-Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
      • 9.4.1.1. China Liquid Biopsy Market (by Therapeutic Application)
    • 9.4.2. Japan
      • 9.4.2.1. Japan Liquid Biopsy Market (by Therapeutic Application)
    • 9.4.3. India
      • 9.4.3.1. India Liquid Biopsy Market (by Therapeutic Application)
    • 9.4.4. Australia
      • 9.4.4.1. Australia Liquid Biopsy Market (by Therapeutic Application)
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea Liquid Biopsy Market (by Therapeutic Application)
    • 9.4.6. Singapore
      • 9.4.6.1. Singapore Liquid Biopsy Market (by Therapeutic Application)
    • 9.4.7. Rest-of-Asia-Pacific
  • 9.5. Latin America and Middle East
    • 9.5.1. Brazil
      • 9.5.1.1. Brazil Liquid Biopsy Market (by Therapeutic Application)
    • 9.5.2. Mexico
      • 9.5.2.1. Mexico Liquid Biopsy Market (by Therapeutic Application)
    • 9.5.3. Saudi Arabia
      • 9.5.3.1. Saudi Arabia Liquid Biopsy Market (by Therapeutic Application)
    • 9.5.4. Rest-of-Latin America and Middle East
  • 9.6. Rest-of-the-World

10. Company Profiles

  • 10.1. Overview
    • 10.1. Abcodia Ltd.
      • . 10.1.1. Company Overview
      • . 10.1.2. Role of Abcodia Ltd. in the Liquid Biopsy Market
      • . 10.1.3. SWOT Analysis
  • 10.2. Adaptive Biotechnologies
    • 10.2.1. Company Overview
    • 10.2.2. Role of Adaptive Biotechnologies Corporation in the Liquid Biopsy Market
    • 10.2.3. SWOT Analysis
  • 10.3. ANGLE plc
    • 10.3.1. Company Overview
    • 10.3.2. Role of ANGLE plc in the Liquid Biopsy Market
    • 10.3.3. Financials
      • 10.3.3.1. Key Insights on the Financial Health of the Company
    • 10.3.4. Global Presence
    • 10.3.5. SWOT Analysis
  • 10.4. Biocept, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Role of Biocept, Inc. in Liquid Biopsy Market
    • 10.4.3. Financials
    • 10.4.4. Key Insights about Financial Health of the Company
    • 10.4.5. SWOT Analysis
  • 10.5. Bio-Rad Laboratories, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Role of Bio-Rad Laboratories, Inc. in Liquid Biopsy Market
    • 10.5.3. Financials
    • 10.5.4. Key Insights about Financial Health of the company
    • 10.5.5. Global Presence
    • 10.5.6. SWOT Analysis
  • 10.6. Cynvenio Biosystems, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Role of Cynvenio Biosystems, Inc. in the Liquid Biopsy Market
    • 10.6.3. SWOT Analysis
  • 10.7. Chronix Biomedical
    • 10.7.1. Company Overview
    • 10.7.2. Role of Chronix Biomedical in the Liquid Biopsy Market
    • 10.7.3. SWOT Analysis
  • 10.8. Epic Sciences, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Role of Epic Sciences, Inc. in the Liquid Biopsy in the Market
    • 10.8.3. SWOT Analysis
  • 10.9. F. Hoffmann-La Roche AG
    • 10.9.1. Company Overview
    • 10.9.2. Role of F. Hoffmann-La Roche AG in the Liquid Biopsy Market
    • 10.9.3. Financials
    • 10.9.4. Key Insights about Financial Health of the company
    • 10.9.5. Global Presence
    • 10.9.6. SWOT Analysis
  • 10.10. GUARDANT HEALTH, INC
    • 10.10.1. Company Overview
    • 10.10.2. Role of GUARDANT HEALTH, Inc. in Liquid Biopsy Market
    • 10.10.3. SWOT Analysis
  • 10.11. Illumina, Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Role of Illumina, Inc. in the Liquid Biopsy Market
    • 10.11.3. Financials
    • 10.11.4. Key Insights about Financial Health of the Company
    • 10.11.5. Global Presence
    • 10.11.6. SWOT Analysis
  • 10.12. MDxHealth, Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Role of MDxHealth, Inc. in the Liquid Biopsy Market
    • 10.12.3. Financials
    • 10.12.4. Key Insights on the Financial Health of the Company
    • 10.12.5. Global Presence
    • 10.12.6. SWOT Analysis
  • 10.13. Menarini Silicon Biosystems, Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Role of Menarini Silicon Biosystems in the Liquid Biopsy Market
    • 10.13.3. SWOT Analysis
  • 10.14. Myriad Genetics, Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Role of Myriad Genetics, Inc. in Liquid Biopsy Market
    • 10.14.3. Financials
      • . 10.14.3.1. Key Insights of the Financial Health of the Company
    • 10.14.4. Global Presence
    • 10.14.5. SWOT Analysis
  • 10.15. Natera, Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Role of Natera, Inc. in the Liquid Biopsy Market
    • 10.15.3. Financials
      • . 10.15.3.1. Key Insights of the Financial Health about the Company
    • 10.15.4. Global Presence
    • 10.15.5. SWOT Analysis
  • 10.16. NeoGenomics Laboratories, Inc.
    • 10.16.1. Company Overview
    • 10.16.2. Role of NeoGenomics Laboratories, Inc. in the Liquid Biopsy Market
    • 10.16.3. Financials
      • . 10.16.3.1. Key Insights on the Financial Health of the Company
    • 10.16.4. Global Presence
    • 10.16.5. SWOT Analysis
  • 10.17. Personal Genome Diagnostics, Inc.
    • 10.17.1. Company Overview
    • 10.17.2. Role of Personal Genome Diagnostics, Inc. in Liquid Biopsy Market
    • 10.17.3. SWOT Analysis
  • 10.18. Qiagen N.V.
    • 10.18.1. Company Overview
    • 10.18.2. Role of Qiagen N.V. in the Liquid Biopsy Market
    • 10.18.3. Financials
      • . 10.18.3.1. Key Insights on the Financial Health of the Company
    • 10.18.4. Global Presence
    • 10.18.5. SWOT Analysis
  • 10.19. Resolution Bioscience, Inc.
    • 10.19.1. Company Overview
    • 10.19.2. Role of Resolution Biosciences, Inc. in the Liquid Biopsy Market
    • 10.19.3. SWOT Analysis
  • 10.20. Sysmex Corporation
    • 10.20.1. Company Overview
    • 10.20.2. Role of Sysmex Corporation in the Liquid Biopsy Market
    • 10.20.3. Financials
    • 10.20.4. Key Insights of the Financial Health of the Company
    • 10.20.5. Global Presence
    • 10.20.6. SWOT Analysis
  • 10.21. Thermo Fisher Scientific
    • 10.21.1. Company Overview
    • 10.21.2. Role of Thermo Fisher Scientific in the Liquid Biopsy Market
    • 10.21.3. Financials
      • . 10.21.3.1. Key Insights on the Financial Health of the Company
    • 10.21.4. Global Presence
    • 10.21.5. SWOT Analysis

11. Research Scope and Methodology

  • 11.1. Report Scope
  • 11.2. Global Liquid Biopsy Market: Research Methodology
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research